Top Markets
#1 Celer Network Celer Network +41.22%
#2 Gravity Gravity +22.02%
#3 Galxe Galxe +19.80%
#4 MemeCore MemeCore +12.58%
#5 Ontology Gas Ontology Gas +9.96%
#6 Cartesi Cartesi +8.25%
#7 Zilliqa Zilliqa +7.90%
#8 Synapse Synapse +7.43%
#9 Cortex Cortex +7.33%
#10 UnifAI Network UnifAI Network +7.06%
Coin of the day
Celer Network Celer Network
Settings
Language
ENGLISH
Currency
USD
Theme
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rank in Stocks #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Share Price
$0.1559364
Last synced: 2026-09-18
Market Cap
$195.17K
Change (1 day)
6.60%
Change (1 year)
-30.91%
Country
GB
Trade Fusion Antibodies plc (FAB)

Category

Healthcare
P/S ratio for Fusion Antibodies plc (FAB)
P/S ratio as of September 2026 TTM: 7.25
According to Fusion Antibodies plc latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.25. At the end of 2024 the company had a P/S ratio of 1.88.
P/S ratio history for Fusion Antibodies plc from 2013 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
2026 (TTM) 7.25 141.79%
2025 3.00 59.38%
2024 1.88 -45.47%
2023 3.45 6.43%
2022 3.24 -66.20%
2021 9.60 78.11%
2020 5.39 86.72%
2019 2.89 -54.34%
2018 6.32 -55.67%
2017 14.25 -22.61%
2016 18.42 -38.61%
2015 30.00 -20.48%
2014 37.73 -43.99%
2013 67.37 0.00%
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.44 43.99%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.01 65.53%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
26.12 260.14%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.76 -48.23%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH